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Abstract
Background: HIV prevalence among pregnant women in Southern Africa is extremely high. Epidemiological studies suggest
that pregnancy increases the risk of HIV sexual acquisition and that HIV infections acquired during pregnancy carry higher
risk of mother-to-child transmission (MTCT). We analyze the potential benefits from extending the availability of effective
microbicide to pregnant women (in addition to non-pregnant women) in a wide-scale intervention.
Methods and Findings: A transmission dynamic model was designed to assess the impact of microbicide use in high HIV
prevalence settings and to estimate proportions of new HIV infections, infections acquired during pregnancy, and MTCT
prevented over 10 years. Our analysis suggests that consistent use of microbicide with 70% efficacy by 60% of non-pregnant
women may prevent approximately 40% and 15% of new infections in women and men respectively over 10 years,
assuming no additional increase in HIV risk to either partner during pregnancy (RRHIV/preg = 1). It may also prevent 8–15%
MTCT depending on the increase in MTCT risk when HIV is acquired during pregnancy compared to before pregnancy
(RRMTCT/preg). Extending the microbicides use during pregnancy may improve the effectiveness of the intervention by 10%
(RRHIV/preg = 1) to 25% (RRHIV/preg = 2) and reduce the number of HIV infections acquired during pregnancy by 40% to 70% in
different scenarios. It may add between 6% (RRHIV/preg = 1, RRMTCT/preg = 1) and 25% (RRHIV/preg = 2, RRMTCT/preg = 4) to the
reduction in the residual MTCT.
Conclusion: Providing safe and effective microbicide to pregnant women in the context of wide-scale interventions would
be desirable as it would increase the effectiveness of the intervention and significantly reduce the number of HIV infections
acquired during pregnancy. The projected benefits from covering pregnant women by the HIV prevention programs is
more substantial in communities in which the sexual risk during pregnancy is elevated.
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Introduction
Four clinical trials have shown that oral and topical pre-
exposure prophylaxis (PrEP) based on tenofovir may be effective in
preventing HIV transmission [1–4]. Although these positive
findings were not confirmed by other trials [5,6] a tenofovir
based product (Truvada) has been approved for PrEP use in the
US [7] and recommended as a preventive option to MSM in
South Africa [8]. It is unclear when PrEP will be accessible to
heterosexual men and women but it is clear that considerable
safety data will be needed before it is explicitly recommended for
use by pregnant women.
Pregnancy has been a consistent exclusion criterion for
participation in oral and topical PrEP efficacy trials [1,3,9,10],
and participants who become pregnant during follow up are
temporarily removed from product use due to safety concerns. To
address this lack of safety data, numerous studies have been
undertaken to gather data that will inform safe use of HIV
prevention agents in pregnancy. The first clinical study of single-
dose Tenofovir gel applied during late pregnancy reported no
adverse effects despite evidence of a trace of absorption of the
product in the maternal and cord blood [11]. A subsequent trial is
currently enrolling HIV negative women in the third trimester of
pregnancy to test the expanded safety of multiple dosing of
Tenofovir gel [12]. A separate observational cohort investigation is
concurrently enrolling women who have become pregnant during
microbicide or oral PrEP trials to investigate inadvertent exposure
to HIV prevention study agents early in gestation [13]. If these
parallel studies in pregnant women demonstrate safety they might
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allow women who become pregnant to receive faster access to the
product after its approval.
Published analyses suggest that pregnant women are among
those who can highly benefit from novel HIV prevention methods.
Recent studies report that the risk of HIV acquisition during
pregnancy is elevated for pregnant women and even for their male
partners in serodiscordant couples [14,15]. Gray and colleagues
estimated that the HIV incidence rate during pregnancy is 2.3%
compared to 1.1% in the non-pregnant and non-lactating women
in Rakai, Uganda [14]. They suggested that increased risk during
pregnancy might be attributable to hormonal changes rather than
sexual risk behavior. A study conducted by the Partners in
Prevention HSV/HIV Transmission Study Team among sero-
discordant couples from seven African countries reported that the
HIV incidence in women is 7.35% versus 3.01% during pregnant
and non-pregnant periods [15]. The HIV incidence of male
partners of pregnant and non-pregnant women was estimated at
3.46% and 1.58%, respectively. These investigators concluded
that the elevated HIV risk associated with pregnancy may be
explained by a combination of behavioral and biological factors.
Both studies outlined the need for additional HIV prevention
efforts during pregnancy to protect mothers, newborns, and
potentially male partners.
High maternal plasma HIV-1 load is a strong predictor for
mother-to-child transmission (MTCT) [16–18]. Assessing the
factors that influence the risk of MTCT in New York, Birkhead
and colleagues estimated that maternal HIV acquisition during
pregnancy is associated with 15-fold increase in transmission risk
[18]. They concluded that avoiding infections during pregnancy
must be among the public-health priorities when MTCT is
addressed. A separate study investigating the prevalence of acute
HIV infections among pregnant women in the US suggests that a
substantial proportion of the perinatal transmission in resource-
rich settings may be caused by HIV acquisitions during pregnancy
[19]. However, a modeling study using data from Zimbabwe
projects that less than 6.2% of the infections in infants occur in
recently seroconverted mothers [20].
In this study mathematical models are used to estimate the
expected population-level benefits from providing effective HIV
prevention means to pregnant women in addition to non-pregnant
women in high prevalence settings. It is assumed that topical PrEP,
with its low level of systemic absorption, will be more appropriate
than oral PrEP as a prevention method for healthy pregnant
women and therefore we use a wide-scale intervention with
vaginal microbicides (VMB) as an example. We assess the
cumulative HIV infections prevented in women and men over
10 years, HIV infections during pregnancy prevented, and the
fractions of MTCT prevented due to VMB use by pregnant
women under various implementation scenarios.
Methods
Transmission Model
We developed a compartmental mathematical model to study
HIV transmission in sexually-active (age 15–49) heterosexual
population (Figure 1). The model is designed to determine what
would be the difference in HIV transmission if intervention with
an effective VMB is rolled out to both pregnant and non-pregnant
women compared to non-pregnant women only. The simulated
population is divided in compartments by gender as men (subscript
g =m) or women (subscript g =w), by HIV status as susceptibles
(S), infected (I), and infected individuals who developed AIDS (A).
Women are additionally stratified by pregnancy status (superscript
p when pregnant) and by VMB use (superscript V for users). Men
and women who become sexually active join the community at
constant rates that are selected to balance the departure rate in a
non-infected population. Adolescents who reach sexual maturity
are assumed to become susceptible to HIV. The rates at which
men and women acquire HIV-infection are derived from standard
binomial models based on the number of sex partners per
susceptible person, the number of sex acts per partnership, the
fraction of sex acts protected by condoms, the protection provided
by VMB (if used) and the HIV acquisition risk per vaginal act for
men and women. Women who decide to use VMB are assumed to
undergo initial and subsequently annual HIV testing. They are
assumed to adhere to VMB use as prescribed, but are removed
from VMB if testing positive for HIV. Complete description of the
model is given in File S1.
Epidemic Settings and Intervention Scenarios
We identified 1000 parameter sets which represent current
epidemic conditions in South Africa. Behavioral and epidemic
parameters are initially varied in experimental parameter ranges
representative for the epidemics in Sub-Saharan Africa (see
Table 1, part A) and posterior parameter sets are preselected to
satisfy the following target criteria: 1) initial HIV prevalence of
15% and 20% among 15–49 year old men and women,
respectively [21]; ii) Annual HIV incidence rate between 0.6%
and 2.5% [22]; iii) Female incidence rate at least 30% higher
than male incidence rate and iv) The absolute difference in
HIV prevalence over 5 years remains below 1% (mature
epidemics). For each set of epidemic parameters we simulate an
HIV epidemic: i) assuming no VMB use; ii) assuming that VMB
is used by proportion of the female population during non-
pregnant periods only (‘‘restricted’’ scenario), iii) assuming that
Figure 1. Flow diagram of the model. Simulated population is
stratified in compartments by gender as men (subscript m) or women
(subscript w) and by HIV status as susceptibles (S), infected with HIV (I)
and sexually inactive due to progression to AIDS (A). Female population
is additionally stratified by pregnancy status (superscript p indicates
pregnancy) and by usage of VMB (superscript p indicates the use of
VMB). VMB users strictly follow the prescribed regimen. A complete
description of the model including the flow rates and the expressions
for the forces of infections (l) is presented in File S1.
doi:10.1371/journal.pone.0073770.g001
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VMB is used by the same proportion of the female population
without interruption during pregnancy (‘‘choice’’ scenario) and
iv) assuming that VMB is used by a fraction of the female
population during non-pregnant periods but by all pregnant
women (‘‘targeted’’ scenario). The effectiveness of the VMB
interventions is measured by the cumulative fraction of new
HIV infections prevented (women, men and total), HIV
infections during pregnancy prevented, and the proportion of
MTCT prevented due to VMB use by pregnant women. All
intervention outcomes are evaluated over 10 years of VMB use.
VMB Efficacy and Intervention Characteristics
The results from CAPRISA-004 suggest that when used
consistently VMB may reduce susceptibility by 54% (95% CI:
4–80%) [1]. In this analysis we explore 50% and 70% reduction
in the HIV acquisition per sex act due to VMB use. Although,
ARV-based VMB may also reduce the infectiousness of the
HIV-positive users we do not consider a reduced risk for the
partners of infected VMB users. To ensure comparability, in all
scenarios we assume that 60% of the sexually active women
start using VMB from the moment of its introduction and
follow strictly the prescribed regimen (perfect adherence). A
fraction of adolescent women who enter the sexually active
population also become VMB users. Although important for the
absolute effectiveness of VMB interventions [23] the assumption
of perfect adherence is unlikely to affect the relative impact of
extending VMB use to pregnant women provided that pregnant
and non-pregnant women use VMB with similar consistency.
Although pregnancy may be a time when women are more
aware of their health and may take measures to increase their
personal protection, we assume that this does not result in
increased adherence to VMB. Conversely, the recent CAPRISA
study looking at pregnancy and study product use suggests that
trial participants who did not use product were more likely to
become pregnant [24]. The model reflects efforts to limit VMB
use by HIV positive women both at the introduction of the
intervention and through periodic HIV screening. No changes
in sexual behavior (frequency of sex acts, condom use rate) due
to the availability of VMB are considered but behavior
alterations during pregnant periods are investigated as described
in the next section. Description of all intervention parameters
and their ranges is presented in Table 2. The effects of key
intervention parameters on the modeling results are studied in a
multivariate sensitivity analysis (see File S1, Fig. S4).
Pregnancy and Risk of HIV Acquisition
We assume a 8–12% annual pregnancy rate among the sexually
active women (15–49 years old) in South Africa which corresponds
to 3–4 pregnancies in a lifetime [25]. Two major scenarios with
respect to the HIV risk during pregnancy (RRHIV/preg) are
considered. In the baseline scenario we assume that the probability
to be infected with HIV does not change during prenatal periods
(RRHIV/preg = 1). In the alternative scenario the HIV risk for
pregnant women is doubled (RRHIV/preg = 2) due to increased
biological susceptibility and/or behavior alterations (reduced
condom use rate) during pregnancy. The cumulative risk per unit
time of pregnant and non-pregnant periods is based on standard
binomial models which estimate the probability to avoid repeated
exposures to HIV (details included in File S1). We identify
combinations of relative susceptibility per act and relative condom
use when pregnant compared to non-pregnant which correspond
to a doubled cumulative risk during pregnancy assuming the same
level of sexual activity as before pregnancy (see Fig. 2A).
Acknowledging the uncertainty about the mechanism of increased
HIV acquisition risk during pregnancy, we explore 3 distinct
combinations of biological and behavioral components, assuming
Table 1. Description and values of the behavioral and epidemic parameters used in the analysis.
Parameter Description Parameter range Ref.
A. Behavioral and epidemic parameters (pre-intervention) Prior range1
bw Female HIV acquisition risk per vaginal act 0.0019–0.0046 [34]
bm Male HIV acquisition risk per vaginal act (50–100%) of bw assumed [34]
1/m Average time (in years) to remain sexually active 35 [35,36]
d, dr Annual rates of progression to AIDS for individuals infected with HIV 0.08–0.14 [37,38]
nw,nm Average number of sexual acts per year for women and men 60–100 [39,40]
rw, rm Average number of sexual partners per year for women and men 1–2 [39,40]
c Rate of condom use in general population 20%–60% [39,40]
ac Condom efficacy per sex act 0.9 [41]
t1 Annual pregnancy rate 8%–12% [25]
t2 Annual rate of return from pregnancy (for women) 1.33 calc.
c Relative rate of condom use during pregnancy compared to when non-pregnant 0%, 50%, 93% calc. Fig.2a
rp Relative HIV acquisition risk per sex act during pregnancy compared to when non-pregnant 1.16, 1.50, 2 calc. Fig.2a
B. Calibrated epidemic data from South Africa
Pw Initial HIV-prevalence (women) 20% [21]
Pm Initial HIV-prevalence (men) 15% [21]
Inc Fitted HIV-incidence (total) 0.6–2.5% [22]
Pr5 Fitted HIV-prevalence in 5 years (total) 16.5%–18.5% assumed
1Ranges for epidemic parameters are sampled uniformly to obtain parameter sets which are filtered to select 1000 epidemics meeting the target criteria about HIV
incidence and HIV prevalence.
doi:10.1371/journal.pone.0073770.t001
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that the higher HIV risk during pregnancy is due to i) substantial
increase in biological susceptibility and small reduction in condom
use (‘‘biological’’ scenario); ii) moderate (42%) increase in
biological susceptibility and 50% reduction in condom use
(‘‘mixed’’ scenario) and iii) small increase (,16%) in susceptibility
and complete elimination of condom use (‘‘behavioral’’ scenario).
VMB interventions under those scenarios are independently
evaluated and compared. We also investigate the possibility that
the risk for MTCT transmission is elevated when HIV is acquired
during pregnancy exploring scenarios in which the relative risk
during pregnancy (RRMTCT/preg) ranges from 1 to 10. HIV
infections of newborn infants are not explicitly modeled but the
relative reduction in MTCT transmission is estimated on the basis
of reduced number of mothers who are HIV-positive as a result of
using VMB.
Results
In this section we present results from modeling simulations
using VMB with 70% efficacy in reducing HIV acquisition risk per
vaginal sex act. Similar results on the usage of 50% efficacious
VMB are included in File S1 (see Fig. S2 and Fig. S3).
Elevated HIV Risk during Pregnancy
First, we study the cumulative risk of HIV acquisition during
pregnancy for different combinations of elevated biological
susceptibility and behavior changes (reduction in condom use)
after conception (Fig. 2A) which both may increase the HIV
acquisition risk during pregnancy. In the case of complete
elimination of condom use and doubled susceptibility per act,
the cumulative risk for pregnant women is more than 3 times
higher compared to non-pregnant periods. The 2-fold increase
reported in some published studies can be obtained by various
combinations of biological and behavioral factors (see the black
line in Fig. 2A). We simulate the elevated HIV risk during prenatal
periods using 3 distinct points along that 2-fold increase curve.
Epidemic Projections with and without VMB
If VMB is not available, a total of 345,000 (90% CI 299,000–
373,000) new HIV infections are expected over 10 years in a
population consisting of 1,000,000 men and same number of
women (Fig. 2B) assuming no change in HIV acquisition risk
during pregnancy (RRHIV/preg = 1). We estimate that under that
scenario approximately 6.8% (90% CI 5.7%–8%) of the newly
infected women acquire HIV when pregnant (Fig. 2C) reflecting
the maximum proportion of infections that an intervention
extended to pregnant women can prevent. Elevated HIV risk
during pregnancy (RRHIV/preg = 2) adds up to 10% to the
cumulative number of infections and increases the share of the
prenatal female infections to 11%–12% with little influence of the
mechanism (combination of condom replacement and increased
susceptibility) causing the increase in HIV acquisition risk. The
overall HIV prevalence in the population after 10 years is
projected to be about 17% under scenarios with the same HIV risk
for pregnant and non-pregnant women and 18% under scenarios
with elevated risk during pregnancy (Fig. 3C).
A consistent use of 70% efficacious VMB by 60% of the non-
pregnant women may prevent about 40% of the new HIV
infections in women over 10 years, assuming no increase in sexual
HIV risk to either partner during pregnancy (RRHIV/preg = 1,
Fig. 3A). The projected fraction of infection prevented drops by 2–
3 percentage points if the HIV risk during pregnancy is elevated
(Fig. 3B). VMB may also contribute to 15% reduction in new male
infections over the same period and lead to a decrease by 3 to 4
percentage points in the overall HIV prevalence expected after 10
years of VMB use (Fig. 3C). However, almost no infections
acquired during pregnancy will be averted in the scenario
excluding pregnant women from VMB use (Fig. 3D) and only
between 8% and 15% of the residual MTCT will be averted
depending on the relative risk of MTCT in case that HIV is
acquired during pregnancy compared to before pregnancy
(Fig. 4A).
Providing VMB to Pregnant Women
The usage of VMB by all pregnant women, may prevent 10–
12% more female infections assuming that the HIV risk during
pregnancy is not elevated (Fig. 3B, black boxes) and almost 25% if
the HIV risk during prenatal periods is doubled (Fig. 3B, colored
boxes). Targeted VMB use by pregnant women may have even
higher contribution to the overall success of the intervention if the
obtained VMB coverage is substantially lower than 60% which we
assumed here (see File S1, Fig. S1). More importantly, the access
of pregnant women to an effective VMB may reduce the number
of HIV infections acquired during pregnancy by 40% to 70% in
the ‘‘choice’’ and ‘‘targeted’’ scenarios, respectively (Fig. 3D). As a
result, additional 6% (RRHIV/preg = 1) to 10% (RRHIV/preg = 2)
absolute reduction in MTCT is projected due to VMB use by
pregnant women assuming no increase in the risk of MTCT when
HIV is acquired after conception (Fig. 4, black boxes). However,
the fraction of MTCT prevented by providing VMB during
pregnancy jumps to 40%–45% if the risk for vertical transmission
increases by 10-fold, when pregnant women become infected
(Fig. 4, green boxes).
Table 2. Description and values of the intervention parameters used in the analysis.
Parameter Description Baseline value (range)1 Ref.
k VMB coverage among adolescent girls reaching sexual maturity 60% (40–80%) assumed
k1 Initial VMB coverage among HIV-negative women 60% (40–80%) assumed
as VMB efficacy in reducing susceptibility per act 50%, 70% (40–80%) assumed [1]
ai VMB efficacy in reducing infectiveness per act 0 (0–50%) assumed
h Prescription rejection rate which measures the reduction in the initial fraction of
HIV-positive compared to HIV-negative women who start using VMB
80% (60–100%) assumed
d Annual withdrawal rate from VMB by HIV+ women as a result of periodic HIV screening 2 (1–3) assumed
1Theranges for intervention parameters are used in multivariate sensitivity analysis (see File S1).
doi:10.1371/journal.pone.0073770.t002
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Discussion
Pregnant women have been recognized as a priority group with
respect to HIV treatment but their needs for HIV prevention have
received less attention. The observed HIV prevalence among
pregnant women in many countries in Southern Africa is
consistently higher than among general female population with
estimates up to 30% for South Africa [26,27]. Almost 40% of the
women who visit prenatal clinics in some provinces of South Africa
test HIV positive [27]. HIV infections acquired during pregnancy
are likely to remain undiscovered and untreated before delivery.
This may seriously increase the risk for both horizontal
transmission to sex partners and vertical transmission to newborn
infants. Evidence has been presented in recent publications that
the HIV acquisition risk during pregnancy is elevated, emphasiz-
ing the need to incorporate these data into planning of wide-scale
prevention interventions (Fig. 2). Studies which disregard this
factor may be underestimating the projected number of infections
over 10 years by 10% and the expected HIV prevalence by 1–2
percentage points.
Providing HIV prevention options to women during pregnancy
is of critical importance. Unfortunately, pregnant women have
been consistently excluded from efficacy trials of oral and topical
PrEP agents which only delays the collection of important safety
data. The predominant reason for this exclusion centers on
concerns for the safety of the fetus [28]. The ethical dilemmas
regarding the enrolling pregnant women in biomedical research
have long been under discussion with a growing number of
researchers advocating for inclusion of pregnant women in clinical
trials [29–31]. A main justification for inclusion of pregnant
women is that preventing the collection of safety and efficacy
information during the prenatal periods in controlled clinical
settings increases the absolute risk for many more users when the
products are licensed, marketed, and then used by the general
population. Thus, considerable inadvertent exposure occurs
because of use of pharmaceutical products by women unaware
of their pregnant status in a less controlled environment than a
clinical trial. Recognizing the harm of delaying effective HIV
preventive tools for pregnant women and the societal benefits of
lessening incident HIV infection during pregnancy, the Microbi-
cide Trial Network has developed a portfolio of clinical trials
which will provide data regarding the safety of promising
microbicides agents [11–13].
Microbicides that protect against HIV and other sexually
transmitted disease and show little systemic absorption in the
maternal bloodstream may be the optimal prevention option for
millions of pregnant and breastfeeding women. We have projected
the impact of wide-scale VMB intervention in high-prevalence
HIV settings representative for the HIV epidemic in South Africa
Figure 2. HIV epidemics and risk of HIV acquisition in absence of VMB. A) Relative HIV acquisition risk during pregnancy compared to non-
pregnant period of the same length for different combinations of biological susceptibility (relative HIV risk per act compared to when not pregnant)
and behavior changes (relative condom use compared to when not pregnant) during pregnancy assuming the same level of sexual activity as before
pregnancy. The black line represents combinations which correspond to 2-fold increase in the cumulative HIV risk during pregnancy. Red dots
represent the parameter combinations used in the explored scenarios; B) Cumulative number of new HIV infections over 10 years and C) Fraction of
the cumulative number of new female HIV infections over 10 years in which HIV is acquired during pregnancy. Presented are scenarios assuming no
change in HIV risk during pregnancy (RRHIV/preg = 1, black boxes) and 3 distinct scenarios assuming 2-fold increase in HIV risk during pregnancy (RRHIV/
preg = 2, colored boxes). The box plots (median, 5th, 25th, 75th, 95th percentiles) reflect the variation in estimates generated by 1,000 simulations in
population with 1 000 000 men and same number of women.
doi:10.1371/journal.pone.0073770.g002
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under different scenarios regarding the access of pregnant women
to the VMB. These analyses suggest that the consistent use of
effective VMB by large proportion of the non-pregnant women
may prevent a substantial fraction of the new infections over 10
years, may reduce the overall HIV prevalence, but will have a little
impact on the HIV infections acquired during pregnancy and on
the residual MTCT. Including pregnant women into the
interventions may have multiple additional beneficial effects. It
would increase the effectiveness of the intervention, most
significantly when sexual risk during pregnancy is elevated
(Fig. 3). More importantly, it may substantially reduce the number
of HIV infections acquired during pregnancy and help prevent
Figure 3. Comparison of the impact of interventions with 70% efficacious VMB used consistently by 60% of the non-pregnant
women under different scenarios of VMB use by pregnant women: A) Cumulative fraction of infections prevented over 10 years in
women (red), men (blue) and total (green) assuming no change in HIV risk during pregnancy (RRHIV/preg =1); B) Cumulative fraction
of infections prevented in women; C) Projected HIV prevalence after 10 years assuming no VMB use and VMB use by non-pregnant
women only. D) Cumulative fraction of infections during pregnancy prevented over 10 years. The scenarios with elevated risk during pregnancy use
parameter combinations described in Fig. 2A. The box plots (median, 5th, 25th, 75th, 95th percentiles) reflect the variation in estimates generated by
1,000 different epidemic sets.
doi:10.1371/journal.pone.0073770.g003
Figure 4. Cumulative fraction of MTCT prevented (right) over 10 years by intervention with 70% efficacious VMB used consistently
by 60% of the non-pregnant women under different scenarios of VMB usage by pregnant women assuming: A) no change in HIV
risk during pregnancy (RRHIV/preg = 1) and B) HIV risk during pregnancy is elevated (RRHIV/preg =2, mixed scenario). The colors
represent different level of the relative risk of MTCT (RRMTCT/preg ) when HIV is acquired during pregnancy compared to when acquired before
pregnancy. The box plots (median, 5th, 25th, 75th, 95th percentiles) reflect the variation in estimates generated by 1,000 different parameters sets.
doi:10.1371/journal.pone.0073770.g004
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large proportion of MTCTs which are escaping the current
PMTCT efforts (Fig. 4).
The results of this analysis are limited to the specific settings
included in the model. The assumptions of instantaneous VMB
uptake by a fraction of the female population and perfect
compliance with the prescribed VMB regimens may overestimate
the overall impact of a VMB intervention but are unlikely to affect
the relative contribution of extending the VMB use to pregnant
women since the adherence is assumed the same for all women
regardless their pregnancy status. Conversely, disregarding a
possible reduction of the infectiousness of HIV-positive users of
VMB may underestimate the overall impact of VMB. However,
the influence of this modeling assumption is limited by the
relatively high withdrawal rate from VMB after HIV acquisition as
reported in other modeling studies [32]. The strict control on the
VMB use by infected individuals will likely prevent the occurrence
of drug-resistance which is not included in our model. The
difference in HIV risk for pregnant and non-pregnant women in
our analysis is based on variation in condom use and per-act
susceptibility to HIV between those periods. However, other
behavioral factors, such as changes in the frequency and type of
sexual activities (anal vs. vaginal sex) may affect the acquisition
risks before, during and after pregnancy [33]. The beneficial
contribution of providing VMB to pregnant women may be
improved or reduced by differential adherence to the product
during pregnancy or by variation in the proportion of non-vaginal
exposures to HIV which we do not discuss in this paper.
The main conclusion of this study is that providing effective and
safe microbicide to pregnant women has public-health significance
and must be among the priorities during the development,
planning and implementation of wide-scale intervention for HIV
prevention.
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